Delivery Order SPE2DB22D1103-SPE2DB24FTCM5
- Not listed
- This federal contract award is for the delivery of 4,560,558,901 units of Epinephrine 0.3 mg auto-injectors to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $4,030.33 and an ultimate completion date of April 12, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of 4,559,427,219 units of Epinephrine 0.3 mg Auto-Injectors, with a ceiling value of $1,779.30. The contract is a Firm Fixed Price Delivery Order with a completion date of December 21, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., to provide 4,560,109,055 units of Epinephrine 0.3 mg auto-injectors. The $2,243.84 firm fixed-price delivery order has a performance period ending on March 2, 2023. This award was not set aside for any specific business category. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award is for the delivery of 4,559,735,721 units of Epinephrine 0.3 mg auto-injectors to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award has a ceiling value of $1,884.05 and is a Firm Fixed Price Delivery Order contract, with an ultimate completion date of January 27, 2023. The contract is not designated with a set-aside. Amerisourcebergen Drug Corp is...
- This federal contract award is for the delivery of 4,566,708,687 units of epinephrine 0.3 mg auto-injectors. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) for a firm fixed price of $2,642.89. The contract has an ultimate completion date of December 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award, valued at $1,186.81, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 0.3 mg Epinephrine auto-injectors, with a completion date of March 31, 2023. The contract is structured as a firm fixed-price delivery order and is not set aside for any specific business type, indicating open competition. Amerisourcebergen Drug Corp is a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,794.36 firm-fixed-price delivery order is for the supply of 4,565,059,491 units of epinephrine 0.3 mg auto-injectors. The contract has an ultimate completion date of July 3, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,283.36 firm fixed-price delivery order is for the supply of 4,568,159,963 units of Epinephrine 0.3 mg auto-injectors. The contract has an ultimate completion date of May 7, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $10,263.76 firm-fixed-price delivery order is for the supply of 4,563,033,632 units of epinephrine 0.3 mg auto-injectors, with a completion date of December 8, 2023. The contract has no set-aside designation, indicating full and open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,094.85 firm fixed-price delivery order is for the supply of 4,568,143,442 units of Epinephrine 0.3 mg auto-injectors. The contract has an ultimate completion date of May 6, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB24FTCM5Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of 4,563,043,090 units of Epinephrine 0.3 mg Auto-Injectors, which are critical medical supplies for military and government healthcare programs. The contract has a ceiling value of $1,564.81 and an ultimate completion date of December 11, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract award is not designated as a set-aside. Amerisourcebergen Drug Corp also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 12/8/23 |